Skip to main content
Top
Published in: BMC Urology 1/2014

Open Access 01-12-2014 | Research article

Preoperative lymphocyte-to-monocyte ratio predicts clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: a retrospective analysis

Authors: Sally Temraz, Deborah Mukherji, Zein Al Abideen Farhat, Rami Nasr, Maya Charafeddine, Mohammed Shahait, Mohammad Rachad Wehbe, Rami Abou Ghaida, Ibrahim Abu Gheida, Ali Shamseddine

Published in: BMC Urology | Issue 1/2014

Login to get access

Abstract

Background

Inflammation is a critical component of tumorigenesis, and many cancers arise from sites of infection, chronic irritation, and inflammation. Inflammatory cytokines triggered by tumors alter hematologic components, including neutrophil, lymphocyte, and monocyte counts. The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios have been shown to be valuable prognostic markers in various types of cancers, including bladder cancer. Risk stratification based on clinicopathologic data is insufficient to support treatment-related choices in patients with bladder cancer. Novel prognostic markers are therefore needed. An elevated pretreatment lymphocyte-to-monocyte ratio (LMR) is reportedly associated with improved overall survival (OS) and a longer time to treatment recurrence (TTR) in some types of cancers. However, these data are lacking in patients with bladder cancer. The aim of the present study was to investigate the effect of the preoperative LMR on OS and TTR in a cohort of patients with bladder cancer.

Methods

Sixty-eight patients with transitional cell carcinoma of the bladder were included in this retrospective analysis. The associations between a high and low LMR with OS and TTR were analyzed using Kaplan–Meier curves and compared by the log-rank test.

Results

In our study cohort, an elevated preoperative LMR was significantly associated with an increased TTR (P = 0.001) and OS (P = 0.020). Patients with an LMR of ≤2.87 showed a median TTR of 2.0 years (95% CI, 0.27–3.73), whereas patients with an LMR of >2.87 had a median TTR of 11.1 years (95% CI, 2.31–19.88) (P = 0.001). Patients with an LMR of ≤2.81 showed a median OS of 2.7 years (95% CI, 0.63–4.70), whereas patients with an LMR of >2.81 had a median OS of 6.0 years (95% CI, 3.60–8.40) (P = 0.020). The clinical stage at diagnosis was the only clinicopathologic feature associated with the LMR, while tumor invasion depth showed borderline significance.

Conclusions

The LMR is an easily measured and inexpensive prognostic marker that was significantly correlated with OS and TTR in the present retrospective analysis. However, because of the small sample size in this study, larger multicenter, prospective studies are needed.
Appendix
Available only for authorised users
Literature
2.
go back to reference Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation. Nature. 2008, 454 (7203): 436-444. 10.1038/nature07205.CrossRefPubMed Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation. Nature. 2008, 454 (7203): 436-444. 10.1038/nature07205.CrossRefPubMed
3.
go back to reference Castelao JE, Yuan JM, Gago-Dominguez M, Yu MC, Ross RK: Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer. 2000, 82 (7): 1364-1369.CrossRefPubMedPubMedCentral Castelao JE, Yuan JM, Gago-Dominguez M, Yu MC, Ross RK: Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer. 2000, 82 (7): 1364-1369.CrossRefPubMedPubMedCentral
4.
go back to reference Gomez D, Farid S, Malik HZ, Young AL, Toogood GJ, Lodge JP, Prasad KR: Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg. 2008, 32 (8): 1757-1762. 10.1007/s00268-008-9552-6.CrossRefPubMed Gomez D, Farid S, Malik HZ, Young AL, Toogood GJ, Lodge JP, Prasad KR: Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg. 2008, 32 (8): 1757-1762. 10.1007/s00268-008-9552-6.CrossRefPubMed
5.
go back to reference Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, Lee K: Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother. 2009, 58 (1): 15-23. 10.1007/s00262-008-0516-3.CrossRefPubMed Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, Lee K: Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother. 2009, 58 (1): 15-23. 10.1007/s00262-008-0516-3.CrossRefPubMed
6.
go back to reference Idowu OK, Ding Q, Taktak AF, Chandrasekar CR, Yin Q: Clinical implication of pretreatment neutrophil to lymphocyte ratio in soft tissue sarcoma. Biomarkers. 2012, 17 (6): 539-544. 10.3109/1354750X.2012.699554.CrossRefPubMed Idowu OK, Ding Q, Taktak AF, Chandrasekar CR, Yin Q: Clinical implication of pretreatment neutrophil to lymphocyte ratio in soft tissue sarcoma. Biomarkers. 2012, 17 (6): 539-544. 10.3109/1354750X.2012.699554.CrossRefPubMed
7.
go back to reference Kwon HC, Kim SH, Oh SY, Lee S, Lee JH, Choi HJ, Park KJ, Roh MS, Kim SG, Kim HJ: Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers. 2012, 17 (3): 216-222. 10.3109/1354750X.2012.656705.CrossRefPubMed Kwon HC, Kim SH, Oh SY, Lee S, Lee JH, Choi HJ, Park KJ, Roh MS, Kim SG, Kim HJ: Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers. 2012, 17 (3): 216-222. 10.3109/1354750X.2012.656705.CrossRefPubMed
8.
go back to reference Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, Thavaramara T: Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. J Gynecol Oncol. 2012, 23 (4): 265-273. 10.3802/jgo.2012.23.4.265.CrossRefPubMedPubMedCentral Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, Thavaramara T: Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. J Gynecol Oncol. 2012, 23 (4): 265-273. 10.3802/jgo.2012.23.4.265.CrossRefPubMedPubMedCentral
9.
go back to reference Xue P, Kanai M, Mori Y, Nishimura T, Uza N, Kodama Y, Kawaguchi Y, Takaori K, Matsumoto S, Uemoto S, Chiba T: Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients. Cancer Med. 2014, 3 (2): 406-415. 10.1002/cam4.204.CrossRefPubMedPubMedCentral Xue P, Kanai M, Mori Y, Nishimura T, Uza N, Kodama Y, Kawaguchi Y, Takaori K, Matsumoto S, Uemoto S, Chiba T: Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients. Cancer Med. 2014, 3 (2): 406-415. 10.1002/cam4.204.CrossRefPubMedPubMedCentral
10.
go back to reference Viers BR, Boorjian SA, Frank I, Tarrell RF, Thapa P, Karnes RJ: Thompson RH. 2014, Pretreatment Neutrophil-to-Lymphocyte Ratio Is Associated with Advanced Pathologic Tumor Stage and Increased Cancer-specific Mortality Among Patients with Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy. Eur Urol: Tollefson MK Viers BR, Boorjian SA, Frank I, Tarrell RF, Thapa P, Karnes RJ: Thompson RH. 2014, Pretreatment Neutrophil-to-Lymphocyte Ratio Is Associated with Advanced Pathologic Tumor Stage and Increased Cancer-specific Mortality Among Patients with Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy. Eur Urol: Tollefson MK
11.
go back to reference Hermanns T, Bhindi B, Wei Y, Yu J, Noon AP, Richard PO, Bhatt JR, Almatar A, Jewett MA, Fleshner NE, Zlotta AR, Templeton AJ, Kulkarni JS: Pre-treatment neutrophil-to-lymphocyte ratio as predictor of adverse outcomes in patients undergoing radical cystectomy for urothelial carcinoma of the bladder. Br J Cancer. 2014, 111 (3): 444-451. 10.1038/bjc.2014.305.CrossRefPubMedPubMedCentral Hermanns T, Bhindi B, Wei Y, Yu J, Noon AP, Richard PO, Bhatt JR, Almatar A, Jewett MA, Fleshner NE, Zlotta AR, Templeton AJ, Kulkarni JS: Pre-treatment neutrophil-to-lymphocyte ratio as predictor of adverse outcomes in patients undergoing radical cystectomy for urothelial carcinoma of the bladder. Br J Cancer. 2014, 111 (3): 444-451. 10.1038/bjc.2014.305.CrossRefPubMedPubMedCentral
12.
go back to reference Canter D, Long C, Kutikov A, Plimack E, Saad I, Oblaczynski M, Zhu F, Viterbo R, Chen DY, Uzzo RG, Greenberg RE, Boorjian SA: Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy. BJU Int. 2011, 107 (1): 58-62. 10.1111/j.1464-410X.2010.09442.x.CrossRefPubMed Canter D, Long C, Kutikov A, Plimack E, Saad I, Oblaczynski M, Zhu F, Viterbo R, Chen DY, Uzzo RG, Greenberg RE, Boorjian SA: Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy. BJU Int. 2011, 107 (1): 58-62. 10.1111/j.1464-410X.2010.09442.x.CrossRefPubMed
13.
go back to reference Hoffmann TK, Dworacki G, Tsukihiro T, Meidenbauer N, Gooding W, Johnson JT, Whiteside TL: Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res. 2002, 8 (8): 2553-2562.PubMed Hoffmann TK, Dworacki G, Tsukihiro T, Meidenbauer N, Gooding W, Johnson JT, Whiteside TL: Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res. 2002, 8 (8): 2553-2562.PubMed
14.
go back to reference Gabrilovich DI, Nagaraj S: Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009, 9 (3): 162-174. 10.1038/nri2506.CrossRefPubMedPubMedCentral Gabrilovich DI, Nagaraj S: Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009, 9 (3): 162-174. 10.1038/nri2506.CrossRefPubMedPubMedCentral
15.
go back to reference Li ZM, Huang JJ, Xia Y, Sun J, Huang Y, Wang Y, Zhu YJ, Li YJ, Zhao W, Wei WX, Lin TY, Huang HQ, Jiang WQ: Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP. PLoS One. 2012, 7 (7): e41658-10.1371/journal.pone.0041658.CrossRefPubMedPubMedCentral Li ZM, Huang JJ, Xia Y, Sun J, Huang Y, Wang Y, Zhu YJ, Li YJ, Zhao W, Wei WX, Lin TY, Huang HQ, Jiang WQ: Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP. PLoS One. 2012, 7 (7): e41658-10.1371/journal.pone.0041658.CrossRefPubMedPubMedCentral
16.
go back to reference Porrata LF, Ristow K, Colgan JP, Habermann TM, Witzig TE, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski GS, Thompson C, Markovic SN: Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. Haematologica. 2012, 97 (2): 262-269. 10.3324/haematol.2011.050138.CrossRefPubMedPubMedCentral Porrata LF, Ristow K, Colgan JP, Habermann TM, Witzig TE, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski GS, Thompson C, Markovic SN: Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. Haematologica. 2012, 97 (2): 262-269. 10.3324/haematol.2011.050138.CrossRefPubMedPubMedCentral
17.
go back to reference Stotz M, Pichler M, Absenger G, Szkandera J, Arminger F, Schaberl-Moser R, Samonigg H, Stojakovic T, Gerger A: The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer. Br J Cancer. 2014, 110 (2): 435-440. 10.1038/bjc.2013.785.CrossRefPubMed Stotz M, Pichler M, Absenger G, Szkandera J, Arminger F, Schaberl-Moser R, Samonigg H, Stojakovic T, Gerger A: The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer. Br J Cancer. 2014, 110 (2): 435-440. 10.1038/bjc.2013.785.CrossRefPubMed
18.
go back to reference Szkandera J, Gerger A, Liegl-Atzwanger B, Absenger G, Stotz M, Friesenbichler J, Trajanoski S, Stojakovic T, Eberhard K, Leithner A, Pichler M: The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas. Int J Cancer. 2014, 135 (2): 362-370. 10.1002/ijc.28677.CrossRefPubMed Szkandera J, Gerger A, Liegl-Atzwanger B, Absenger G, Stotz M, Friesenbichler J, Trajanoski S, Stojakovic T, Eberhard K, Leithner A, Pichler M: The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas. Int J Cancer. 2014, 135 (2): 362-370. 10.1002/ijc.28677.CrossRefPubMed
19.
go back to reference Michaud DS: Chronic inflammation and bladder cancer. Urol Oncol. 2007, 25 (3): 260-268. 10.1016/j.urolonc.2006.10.002.CrossRefPubMed Michaud DS: Chronic inflammation and bladder cancer. Urol Oncol. 2007, 25 (3): 260-268. 10.1016/j.urolonc.2006.10.002.CrossRefPubMed
20.
go back to reference Eruslanov E, Neuberger M, Daurkin I, Perrin GQ, Algood C, Dahm P, Rosser C, Vieweg J, Gilbert SM, Kusmartsev S: Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Int J Cancer. 2012, 130 (5): 1109-1119. 10.1002/ijc.26123.CrossRefPubMed Eruslanov E, Neuberger M, Daurkin I, Perrin GQ, Algood C, Dahm P, Rosser C, Vieweg J, Gilbert SM, Kusmartsev S: Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Int J Cancer. 2012, 130 (5): 1109-1119. 10.1002/ijc.26123.CrossRefPubMed
21.
go back to reference Pollard JW: Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004, 4 (1): 71-78. 10.1038/nrc1256.CrossRefPubMed Pollard JW: Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004, 4 (1): 71-78. 10.1038/nrc1256.CrossRefPubMed
22.
go back to reference Condeelis J, Pollard JW: Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006, 124 (2): 263-266. 10.1016/j.cell.2006.01.007.CrossRefPubMed Condeelis J, Pollard JW: Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006, 124 (2): 263-266. 10.1016/j.cell.2006.01.007.CrossRefPubMed
23.
go back to reference Donskov F, von der Maase H: Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol. 2006, 24 (13): 1997-2005. 10.1200/JCO.2005.03.9594.CrossRefPubMed Donskov F, von der Maase H: Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol. 2006, 24 (13): 1997-2005. 10.1200/JCO.2005.03.9594.CrossRefPubMed
24.
go back to reference Takasaki Y, Iwanaga M, Tsukasaki K, Kusano M, Sugahara K, Yamada Y, Kamihira S, Ikeda S, Tomonaga M: Impact of visceral involvements and blood cell count abnormalities on survival in adult T-cell leukemia/lymphoma (ATLL). Leuk Res. 2007, 31 (6): 751-757. 10.1016/j.leukres.2006.11.013.CrossRefPubMed Takasaki Y, Iwanaga M, Tsukasaki K, Kusano M, Sugahara K, Yamada Y, Kamihira S, Ikeda S, Tomonaga M: Impact of visceral involvements and blood cell count abnormalities on survival in adult T-cell leukemia/lymphoma (ATLL). Leuk Res. 2007, 31 (6): 751-757. 10.1016/j.leukres.2006.11.013.CrossRefPubMed
25.
go back to reference Rosenberg SA: Progress in human tumour immunology and immunotherapy. Nature. 2001, 411 (6835): 380-384. 10.1038/35077246.CrossRefPubMed Rosenberg SA: Progress in human tumour immunology and immunotherapy. Nature. 2001, 411 (6835): 380-384. 10.1038/35077246.CrossRefPubMed
26.
go back to reference Zikos TA, Donnenberg AD, Landreneau RJ, Luketich JD, Donnenberg VS: Lung T-cell subset composition at the time of surgical resection is a prognostic indicator in non-small cell lung cancer. Cancer Immunol Immunother. 2011, 60 (6): 819-827. 10.1007/s00262-011-0996-4.CrossRefPubMedPubMedCentral Zikos TA, Donnenberg AD, Landreneau RJ, Luketich JD, Donnenberg VS: Lung T-cell subset composition at the time of surgical resection is a prognostic indicator in non-small cell lung cancer. Cancer Immunol Immunother. 2011, 60 (6): 819-827. 10.1007/s00262-011-0996-4.CrossRefPubMedPubMedCentral
27.
go back to reference Soygür T, Bedük Y, Yaman O, Yilmaz E, Tokgöz G, Gögüş O: Analysis of the peripheral blood lymphocyte subsets in patients with bladder carcinoma. Urology. 1999, 53 (1): 88-91. 10.1016/S0090-4295(98)00447-6.CrossRefPubMed Soygür T, Bedük Y, Yaman O, Yilmaz E, Tokgöz G, Gögüş O: Analysis of the peripheral blood lymphocyte subsets in patients with bladder carcinoma. Urology. 1999, 53 (1): 88-91. 10.1016/S0090-4295(98)00447-6.CrossRefPubMed
28.
go back to reference Kastelan Z, Lukac J, Derezić D, Pasini J, Kusić Z, Sosić H, Kastelan M: Lymphocyte subsets, lymphocyte reactivity to mitogens, NK cell activity and neutrophil and monocyte phagocytic functions in patients with bladder carcinoma. Anticancer Res. 2003, 23 (6D): 5185-5189.PubMed Kastelan Z, Lukac J, Derezić D, Pasini J, Kusić Z, Sosić H, Kastelan M: Lymphocyte subsets, lymphocyte reactivity to mitogens, NK cell activity and neutrophil and monocyte phagocytic functions in patients with bladder carcinoma. Anticancer Res. 2003, 23 (6D): 5185-5189.PubMed
Metadata
Title
Preoperative lymphocyte-to-monocyte ratio predicts clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: a retrospective analysis
Authors
Sally Temraz
Deborah Mukherji
Zein Al Abideen Farhat
Rami Nasr
Maya Charafeddine
Mohammed Shahait
Mohammad Rachad Wehbe
Rami Abou Ghaida
Ibrahim Abu Gheida
Ali Shamseddine
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2014
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/1471-2490-14-76

Other articles of this Issue 1/2014

BMC Urology 1/2014 Go to the issue